Weinong Guo

Weinong Guo currently serves as Senior Vice President of Clinical Development at Alnylam Pharmaceuticals, focusing on advancing global RNAi programs in cardiometabolic and prevalent disease therapeutic areas since May 2021. Prior to this role, Guo was Head of Development at HENGRUI USA LTD, responsible for clinical development and registration of innovative pipelines across various therapeutic areas. Guo has extensive experience from Novartis, where roles included Sr. Global Clinical Program Head and Sr. Global Program Clinical Head in cardiovascular, renal, and metabolism development, leading pivotal phase 2/3 clinical trials. Additionally, Guo held positions at Schering-Plough, Solvay Pharmaceuticals, Lundbeck Research USA, and Washington University School of Medicine. Guo holds a PhD in Cardiac Electrophysiology from Nagoya University and an MD from Soochow University.